Dr Suchitra Sundaram reflects on time limited venetoclax combinations, next generation non covalent BTK inhibitors, and novel ...

Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Sequential BCL2 inhibitor therapy shows initial responses but lacks durability, especially in patients exposed to both BTKi ...

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Recent years have brought more targeted agents to the frontline treatment for patients with chronic lymphocytic leukemia. Strides have been made for the frontline treatment of patients with chronic ...